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Abstract
Background: Current practice guidelines for schizophrenia care recommend that antipsychotic medication is
essential for patients’ long-term maintenance treatment but their non-adherence to this medication is still a main
obstacle to relapse prevention. This study evaluated the effects of a motivational-interviewing-based adherence
therapy for people with schizophrenia spectrum disorders.
Methods: This randomised controlled trial was conducted with 134 outpatients with schizophrenia spectrum
disorders; 67 of them received a six-session adherence therapy (in addition to usual care) and 67 received usual
psychiatric care alone. Participants’ outcome measures included symptom severity, medication adherence,
hospitalisation rates, insight into illness/treatment, and functioning.
Results: The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003),
insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and
medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone.
Conclusions: Motivational-interviewing-based adherence therapy can be an effective approach to treatment for
people with early stage of schizophrenia who poorly adhere to medication regimen.
Trial registration: ClinicalTrials.gov NCT01780116, registration date January 29, 2013.
Keywords: Adherence therapy, Antipsychotics, Randomised controlled trial, Motivational interviewing,
Schizophrenia, Insight into treatment
Background
Schizophrenia and its spectrum disorders is a major
group of serious mental illnesses that induces disabling
residual and remitted symptoms and high relapse rates
in psychiatric rehabilitation globally [1]. While current
guidelines for schizophrenia care recommend anti-
psychotic medication to be essential for long-term main-
tenance treatment, non-adherence to this medication is
found to be a predictor factor for re-hospitalisation and
relapse [1, 2]. It is also recommended that mental
healthcare interventions and services should explicitly
direct healthcare providers to ensure that early psychosis
intervention teams are in place and provide appropriate
psychosocial interventions for these people within the
‘critical period’ (i.e., the first 3 years of illness), which
can address their specific needs for better engaging and
retaining in the services/interventions provided, en-
hanced insight into the illness and its treatment and op-
timal self-management of the illness [3]. Therefore, it
can facilitate early recovery and prevent their progres-
sion to chronic illness.
Systematic reviews on clinical trials of treatments in
psychosis, particularly those with chronic psychosis, sug-
gest that these patients’ adherence to oral antipsychotics
are generally poor with average adherence rates of 30–
50 % [4, 5]. Despite the advent of new (atypical)
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antipsychotics with less side-effects, some side-effects of
these novel drugs such as tardive dysknesia and obesity
are severe. While there has been increasing number of
patients using these atypical antipsychotics, there is little
evidence that progress has been made on increasing
these patients’ medication adherence. Poor medication
and other treatment compliance may then result in fre-
quent recurrences and high relapses from schizophrenia,
which would much increase the medical costs and bur-
den of society, for example, ranging from U.S. dollars of
4–12 billion and contributing to 2–5 % of the total med-
ical or Medicare costs of developed countries [1, 5].
Early intervention for people with first-episode or recent
onset psychosis involving education and experiential
learning in dimensions of awareness of illness, relabeling
of symptoms and need for treatment is considered es-
sential to enhance their motivation to engage in psycho-
social intervention and rehabilitation programmes [3].
Adherence therapy may be useful for these peoples with
early psychosis to improve their insight to the illness
and its medication/treatments, and enhance their motiv-
ation and self-efficacy in self-management of their illness
and relapse prevention [6, 7].
‘Adherence’, sometimes interchangeably with ‘compli-
ance’, means that a client accepts the advice of health-
care professionals to take medication according to a
medical prescription, and it reflects the client’s perspec-
tive regarding the importance and purpose of taking the
prescribed medication [4, 6]. Nevertheless, the effects of
psycho-education and other models of psychosocial
intervention on adherence to medication in schizophre-
nia are multifaceted and complex, with modest and in-
consistent effects on successfully improving patients’
treatment adherence, functioning and/or other psycho-
social outcomes [2, 5, 6]. For instance, psycho-education
programs for people with psychotic disorders aimed to
enhance knowledge about mental illness and its medica-
tions/treatments; however, the findings of most recent
studies were non-significant on promoting positive atti-
tudinal and behavioural changes in these patients’ treat-
ment adherence and improve the service utilization and
re-hospitalisation rate [3, 7–9].
While poor insight has shown to be associated with
poor outcome in schizophrenia [10], insight is regarded
as a multi-dimensional construct with at least three in-
terrelated components, including awareness of having a
mental illness, understanding the need for treatment and
its compliance, and the ability to re-evaluate and re-label
unusual events as pathological [11]. These components
of insight appear to be distinct constructs with different
neurocognitive and psychosocial correlates [12, 13].
Acute and severe psychopathology (e.g., suspicions and
delusional beliefs) and any delay in seeking treatment
during the early stages of schizophrenia associated with
insight into the illness can render it difficult for prompt
and efficacious interventions and understanding about
the significance of medication adherence, thus reducing
the likelihood of their adherence behaviours [7, 9]. Pa-
tients’ insight into treatment can be associated with their
negative symptoms and internalized stigma.
This may be because similar to other chronic illnesses,
these interventions have inadequately focused on facili-
tating these patients to accept their illness and its treat-
ment and/or resolve their resistance or ambivalence to
changing their lifestyle and behaviours, as required by
the treatment regimen [2, 7]. Most approaches to psy-
chosocial intervention in schizophrenia mainly provide
knowledge of the illness and its treatment and prognosis,
perceived (or experienced) stigma, coping and behav-
ioural adjustments, and therapeutic alliance with pro-
fessionals. However as suggested by recent expert
consensus guidelines for schizophrenia treatment [1, 6],
motivational interviewing (MI) technique has recently
been adopted in adherence therapy (AT) for people with
schizophrenia to enhance their adherence to medication
by helping them understand and accept their medication
receiving and cope with the life situations concerning
the adverse effects of the medication taken. Unlike most
of the other psycho-educational and behavioural ap-
proaches to medication adherence, MI is a goal-directed,
patient-centred interventional style, which specifically
works on facilitating and engaging intrinsic motivation
within individual patients and helps them explore and
resolve ambivalence to an adherence behaviour, for
empowering them to consider making changes in such
non-adherence [7, 14]. The MI-based intervention has
demonstrated preliminary positive evidence on reducing
psychotic symptoms and relapse rate in a few European
countries and Thailand [7–10]. Therefore, this study
aimed to evaluate the effect of adherence therapy for
Chinese people with schizophrenia and its subtypes on
symptom severity, medication adherence, re-hospitalization
rate, functioning, and insight into illness/treatment over a
18-month follow-up, when compared with those receiving
treatment as usual (TAU). It was hypothesised that that the
AT group would demonstrate significantly greater improve-
ments on symptom severity and other clinical outcomes
(e.g., medication adherence and re-hospitalization rates,
and insight into illness/treatment) at immediately and over
18 months after completion of the intervention, than the
TAU group.
Methods
This was a single-blind randomised controlled trial of a
motivational interviewing-based adherence therapy for
outpatients with schizophrenia spectrum disorders,
using a repeated-measures control group design and an
intention-to-treat basis. The trial was undertaken in
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Hong Kong between December 2012 and May 2015 and
all subjects were assessed by a psychiatrist to be men-
tally competent to follow the instructions of the inter-
vention used and followed up over 18 months (Period:
May 2012-December 2014), respective of whether they
completed the intervention or not.
Participants and settings
The controlled trial was conducted at two Community
Psychiatric Nursing Services (CPNS) in the two largest
geographical regions of Hong Kong (i.e., the New Terri-
tories and Kowloon). There were 3000 patients with
schizophrenia and its subtypes such as schizoaffective
and schizophreniform disorders; of which, 1200 were eli-
gible participants (40 % of the total patient population)
who met the study criteria at below and were accessible.
The main reasons for those excluded from this study
(as shown in Fig. 1) included: good medication compli-
ance (n = 600), unable to be accessed (n = 200), having
chronic physical illness or cognitive impairment (n = 350),
and mentally incompetent to participate (n = 450). From
1200 eligible participants with schizophrenia spectrum dis-
orders, 650 (54 %) could be contacted and agreed to partici-
pate and 134 were recruited after obtained their informed
written consent by a research assistant. There were 70 pa-
tients (11 %) approached but refused to participate mainly
due to lack of time or unwillingness to discuss their medi-
cation adherence. Sixty-seven participants per CPNS were
selected randomly from each of the two patient lists (in al-
phabetical order with their names), using computer-
generated random numbers prepared by an independent
statistician. After completed the baseline measures during
home visit, 134 participants were assigned randomly by the
research assistant into either AT or TAU (n = 67 in each
group) by drawing a labelled card (1 = ‘AT’; 2 = ‘TAU’) from
an opaque envelope. The participant list and intervention
assignment were concealed to the researchers, assessors
and outpatient clinic until all data entries were completed.
Patients with schizophrenia spectrum disorders
(according to DSM-IV-TR criteria) [15] from the two
CPNS were included if they were: (a) aged 18–64 years,
Hong Kong residents speaking in Mandarin/Cantonese;
(b) within 3 years of the illness; and (c) poorly adhered
to antipsychotic medication as indicated by the Drug
Attitude Inventory score of 11 or below [7], and/or re-
cent history of non-adherence to medication (i.e., any
cessation of oral antipsychotics associated with psychi-
atric admission for ≥1 per month, or with ≥3 missed
doses/week in the past 3 months [5, 7, 9], as indicated in
their outpatient or CPNS records). Those were excluded
if they had: (a) regular medication of depot/intramuscu-
lar injection(s) only; (b) co-morbidity of learning disability,
organic brain disease and/or a clinically significant medical
disease; (c) already participated in any medication
management programme; and/or (d) supervised medication
taking by health care staff.
Sample size estimation was based on two similar
clinical trials and our pilot study of adherence therapy,
in which symptom severity and/or medication adher-
ence were the primary outcomes [8, 9, 16]. A random
sample of 134 (n = 67 per group) was required to de-
tect significant differences on the two outcomes be-
tween two groups at an effect size of 0.54 (0.58 for
symptoms and 0.50 for adherence) [9, 16], at p = 0.05
(two-sided) and study power of 0.80, with a 20 % of
expected attrition [17].
Procedure
Ethics approval of this trial was granted by the Human
Subjects Research Ethics Sub-Committee of The Hong
Kong Polytechnic University and the Hospital Cluster
Research Ethics Committees of the hospitals (KCH and
CPH) governing the two CPNS. A flow diagram of the
study procedure is attached in Fig. 1 according to the
latest CONSORT statement [18]. All participants were
fully explained about the purpose and procedure of the
study, as well as the confidentiality of data and their
right to withdraw from the study at any time, and then
asked for written consent. With their written consent,
the participants were asked to complete the outcome
measures and demographic and clinical data at recruit-
ment (T0) and 2 weeks (T1), 6 months (T2) and
18 months (T3) after completed 3-month intervention.
Patients’ re-hospitalisations (and its nature such as
voluntary and compulsory) and duration of illness
were checked and confirmed with the patient records
in the CPNS.
Measures
The outcome measures at T0-T3 included: the primary
outcomes, consisting of Adherence Rating Scale (ARS)
and Positive and Negative Syndrome Scale (PANSS); and
the secondary outcomes, including Insight and Treat-
ment Attitudes Questionnaire (ITAQ), Specific Level of
Functioning Scale (SLOF), and number and length (days)
of psychiatric hospitalizations, over the past 4 months.
These scales showed very good internal consistency
among the participants at baseline measurement in this
study (i.e., Cronbach’s alphas were 0.89 for ARS, 0.91 for
PANSS, 0.88 for ITAQ, and 0.93 for SLOF). Total num-
ber and duration (days) of psychiatric re-hospitalisations
of each participant were self-reported by the participants
and then checked against the outpatient clinic/CPNS re-
cords at pre-test and three post-tests. Patients’ demo-
graphic and clinical data (e.g., gender, age, dosage of
antipsychotic medication in terms of haloperidol equiva-
lents [19], and duration of illness) were collected at
recruitment.
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The single-item ARS developed by Staring et al. [10] was
a simple, user-friendly and valid measure to assess level of
medication adherence; whereas, pill counts and urine tests
have recently been recognised for its potential inaccuracy
and time constraints for estimation of usage of anti-
psychotic medication [7, 9]. Items of the ARS were rated
on a 5-point Likert scale (1 = total non-adherence, 2 = poor
adherence, 3 = inadequate adherence, 4 = fair adherence,
and 5 = good adherence) by the research assistant and par-
ticipants’ case manager (community psychiatric nurse), in-
dependently; and their ratings were finalised in consensus
agreement. The scale demonstrated excellent inter-rater
reliability (92–100 % agreement) and content validity in
people with psychotic disorders [16, 20].
Fig. 1 This figure indicates a flow diagram of the controlled trial procedure. One hundred and thirty-four out of 650 approached patients with
schizophrenia spectrum disorders were recruited from two community psychiatric nursing service units (i.e., 67 participants in each setting). After
informed consent and baseline measurement, they were randomly assigned into either adherence therapy (plus usual care, n = 67) or treatment
as usual alone (n = 67) group. Following 3-month intervention, the participants completed the post-test outcome measurements at 2 weeks,
6 months and 18 months follow-up. With an attrition of totally 6 participants, outcome data of 65 in adherence therapy and 63 in treatment as
usual group were finally analysed and compared
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The 30-item PANSS assessed the severity of psych-
otic symptoms on three subscales, including positive
symptoms (7 items), negative symptoms (7 items) and
general psychopathology (16 items) [21]. Items were
scored on an 8-point Likert scale (from 1 = absent to
7 = extreme). The scale indicated a high concurrent
validity with the Brief Psychiatric Rating Scale (Pearson’s
r = 0.85–0.90) and satisfactory test-retest reliability (intra-
class correlation = 0.85–0.90) and internal consistency
(Cronbach’s α = 0.88–0.91) in patients with serious mental
illness [21].
The 11-item ITAQ assessed patients’ insight into their
illness and needs for treatment [22]. Items were rated on
a 3-point Likert scale (0 = no insight; 1 = partial insight
and 2 = good insight); the higher its score, the better was
a person’s insight into the illness and receiving its treat-
ments. The Chinese version indicated satisfactory in-
ternal consistency (Cronbach’s α = 0.82), inter-rater
reliability (intra-class correlation = 0.82), and concurrent
validity with mental status and psychopathology (Pearson’s
r = 0.56 and 0.60, p = 0.001) measurements in Chinese pa-
tients with schizophrenia [16, 23].
The 43-item SLOF assessed three functional domains
of patients with schizophrenia, including self care and
maintenance (12 items), social functioning (14 items)
and community living skills (17 items) [24]. Its items
were rated on a 5-point Likert scale (from 1 = totally
dependent to 5 = highly self-sufficient). The Chinese
version demonstrated satisfactory content validity, test-
retest reliability (intra-class correlation = 0.80), and in-
ternal consistency (Cronbach’s α = 0.88–0.96) in Chinese
patients with schizophrenia [16, 23].
Adherence therapy (AT)
Patients (n = 67) received a 12-week (six 2-h sessions
every 2 weeks) AT modified from Gray et al.’s [7] medi-
cation adherence programmes, in addition to usual
CPNS. Most concepts, topics and content of Gray et al.’s
8-session AT, which was based on Kemp et al.’s [25]
compliance therapy, were adopted, including the ap-
proach and principles of motivational interviewing (MI)
with non-confrontational technique, re-examining and
improving knowledge, attitude (ambivalence) and bar-
riers to medication adherence, planning for problem-
solving and actions for changes in adherence behaviour,
rationalising patient’s beliefs and concerns, and relapse
prevention. The AT conducted by a trained community
psychiatric nurse (nurse therapist) during home visit was
based on the principles of MI, involving cognitive, mo-
tivational, insight-inducing, and behavioural training,
which are viewed as particularly useful for people with
addictive and resistant behaviours or ambivalent to
changing their attitude/behaviour towards psychiatric
treatment [7]. The nurse therapists used the five
principles of MI with a non-confrontational approach,
including expressing empathy, developing discrepancy,
avoiding from argumentation, rolling with resistance,
and supporting self-efficacy [25], for discussing their
attitudes and beliefs towards their illness and medica-
tion adherence. While it was considerably more diffi-
cult to discuss issues of motivation in patients with
severe psychotic (positive and negative) symptoms, MI
combined with principles of cognitive therapy (e.g.,
awareness and acceptance of experiences, problem-
solving and coping skills training, and behavioural re-
hearsals of adherence) was found useful to focus on
particular consequences of illness and treatment be-
haviours on individual patients, thus engaging them in
resolving their ambivalence to their illness-related and
life problems [9, 16].
The AT consisted of three phases (Table 1), adopting a
few strategies to address Chinese cultural tenets (i.e.,
cultivating an open and accepting mode of responses
and expression of feelings, resolving strong self-
centredness, discussing perceived social stigma, and en-
couraging family support and collectivism) [16]. Phase 1
(one session) of AT aimed to engage participants in ad-
dressing their needs and concerns in medication adher-
ence, leading them to set goals and action for change in
non-adherence. Phase 2 (two sessions) focused on edu-
cation about the illness and its treatment, then explored
patients’ strengths and barriers to medication adherence
and facilitated them to recognise main barriers to their
adherence such as perceived stigma, undesirable side-
effects of medication and inadequate social support, and
finally, developed coping strategies in taking medication
over a long term. Phase 3 (three sessions) aimed to ra-
tionalise patients’ beliefs and concerns about medication
management, resolve difficulties in adhering to medica-
tion regimen and improve social network and relation-
ship, thus empowering relapse prevention and better
integration into the community.
The AT was conducted by six community psychiatric
nurses (i.e., three from each CPNS) who received two
full-day training and supervised practices on four pa-
tients based on the AT instructor programme [7, 8]; and
each of them was responsible for 11–12 participants.
The consistency and competency of their implementa-
tion of the AT (i.e., over 90 % of the items rated as
‘competent’) was confirmed, using a validated AT com-
petency scale [9]. Two sessions of each therapist were
randomly selected, audio-taped and assessed by two
raters (first author and one researcher) independently to
monitor the fidelity and competency of implementation
of AT according to the treatment protocol. The fidelity
of their intervention implementation ranged between
91–99 % of the items required and 92–97 % of them also
rated as ‘competent’ (median = 96 %).
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Treatment as usual (TAU)
The TAU group received routine treatment and com-
munity psychiatric nursing service, which were similar
between the two CPNS. The TAU consisted of psychi-
atric consultation and treatment by psychiatrist, home
visits, mental health assessment and brief education
on treatment and medication by community psychi-
atric nurse every 4–6 weeks, and healthcare, social
welfare and financial aids by medical social worker.
Clinical psychologist would also be consulted for
counselling as needed.
Data analyses
Demographic and outcome data of the two study groups
(AT and TAU) were analysed on an intention-to-treat
basis using the IBM’s SPSS version 20.0. A Goodness of
Fit Chi-square (for categorical data) and independent-
sample t-test (for interval/ratio data) were used to test
the heterogeneity of the study groups or settings in
terms of demographic characteristics and outcome mea-
sures at baseline (T0). With too much violations of
assumptions of linearity and homogeneity of variance-
covariance, and multi-collinearity for multivariate
Table 1 Motivational interviewing-based adherence therapy for people with schizophrenia
Phase/Session Interventions Main assignments
Phase 1
(1 session)
Purposes: Reviewing antipsychotic medication use and the impacts
of psychotic symptoms on medication (and treatment)
adherence, the desired and unwanted effects of medication,
anti-psychotic side-effects, and attitude and satisfaction with
medication taking.Examining and addressing beliefs and
concerns towards adherence, and plan for problem-
solving.Homework assignment: Weekly record of adherent
behaviour and reasons for adherence and/or inadequately
or fully non-adherence.
(1) To help participants review their past and present states of taking
antipsychotics; and(2) To assess knowledge, attitude and barriers to
medication adherence and plan for problem-solving and improving
adherence behaviour using a standard assessment form.Participants
identify the present beliefs and concerns, benefits and barriers related
to medication and rated the level of distress (i.e., 1–10) attached to
each of the main side-effects.Family members are asked for giving
their opinions and attitudes towards medication taking by their
relative with schizophrenia.Participants are asked to do home
assignment by recording weekly adherent behaviours and both they
themselves and nurse therapist would keep documentation for
records and reviews.The therapist makes an attempt to link
medication cessation with relapse. Negative treatment experiences
and high levels of distress regarding side-effects are acknowledged
and discussed. Denial of need for treatment is met with gentle
enquiries into the ensuring social/family/lifestyle disruptions.
Phase 2
(2 sessions)
Purposes: Revisiting and revising previous goals or add new ones,
and their actions.Recognising factors that may lead to poor
adherence, and develop coping strategies to reduce urges
for non-adherenceHomework assignment:Practicing new
actions for maintaining or enhancing adherence.Weekly
record of adherent behaviours and reasons for adherence
or non-adherence to medication.
(1) To educate about mental illness and its treatment and care
required;(2) To review the goals, actions and adherence records
of the last two weeks; and(3) To identify barriers to medication
adherence and develop coping strategies, immediate and
longer-term goals/actions.Participants’ misconceptions about
symptoms and side-effects antipsychotic medication will be clarified.
The tendency to stop medication whenever the participants feel well
is to be discussed, and their meanings attached to medication are
explored, that is, an identity as a ‘sick person’.Participants are asked
to weigh up their benefits and drawbacks of treatment and the
nurse therapist ‘home in’ on the benefits, especially when they
emerge spontaneously.Symptoms reported by the participants are
fed back as their needs (‘symptoms’) for treatment.
Phase 3
(3 sessions)
Purposes: Evaluation of the progress of medication adherence with
each participant and his/her change in beliefs/insight into
illness and treatment during session 5.Making future plan
with participants to continue self-monitoring of adherence
and its contractual agreement; and clarifications of means
of support from CPNS, family and services.Homework
assignment:Weekly record of medication behaviours and
reasons for adherence or non-adherence.Risk assessment
for relapse prevention and a list of risk factors identified
and recorded.
(1) To rationalise participant’s beliefs and concerns and to prevent
relapse;(2) To manage social stigma and enhance social
support.Participants are facilitated to identify the characteristics of
prodromal symptoms and the importance of early intervention to
prevent a full-blown episode.In sessions 5 and 6, the nurse therapist
use normalising rationale to deal with stigma towards the illness/
medication; suggest analogy with physical illness requiring
maintenance treatment; and highlight illness prevalence with
examples of ex-patients who have been successful in coping with
difficulties as theirs.Participants reframe medication use by partici
pants as a freely chosen strategy to enhance control of quality of life
and use metaphors of medication as ‘insurance policy’- staying
well.Future plan and contractual agreement are made to continu
ously monitor medication adherence and supporting resources
from CPNS, family and other mental healthcare services are clarified.
CPNS Community Psychiatric Nursing Service
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analyses of variance [17], repeated-measures analysis of
variance (ANOVA) tests were performed for most of the
outcome variables (ITAQ, PANSS, SLOF, ARS, and length
of re-hospitalisations), and Kruskal-Wallis test for the num-
ber of re-hospitalisations, to determine the interaction
(group x time) effects of treatment across time. Helmert’s
contrasts tests would be performed to examine any signifi-
cant between-group differences on individual outcomes at
each of the three post-tests (T1 to T3) if significant
ANOVA results were found. Bonferroni’s corrections were
adopted to adjust level of significance for multiple ANOVA
analyses (i.e., adjusted p value = 0.01) [26]; otherwise, the
level of significance of other statistical tests was set at 0.05.
The ATattendance, study attrition, attendance to other psy-
chosocial interventions, and psychotropic medications used
over the study period were recorded and/or calculated.
Results
Sample characteristics
Of the 134 participants, 128 were included in the final
data analysis (attrition rate = 4.5 %), due to lost to
follow-up at T1 (n = 2 in TAU), mortality (n = 1 in
TAU) and withdrawn from study participation (n = 2
in both AT and TAU). Three participants in AT failed
to attend >3 group sessions and the mean and median
attendance to AT sessions were 4.6 (SD = 1.1) and 5.0
(range 2–6), respectively.
Demographic and clinical characteristics of the 134
participants (Table 2) did not show any statistical differ-
ences between the two groups (p > 0.10). There were also
no statistically significant differences on these character-
istics between these participants and the non-
participants (n = 266) who verbally agreed to participate
(p > 0.20). Majority of them in AT and TAU (n = 57,
85 % and n = 56, 84 %, respectively) were taking a
medium or high dosage of oral anti-psychotic medica-
tion [haloperidol equivalent mean values [19] were
9.1 mg/day (SD = 4.1) and 10.3 mg/day (SD = 5.3), re-
spectively]; whereas, two-thirds were taking atypical
and/or blended mode of anti-psychotics (n = 45 and 47;
67 and 70 %). Their average duration of illness was
around 28 months (range 3–36 months). More than half
(n = 36 in AT and 38 in TAU) were living with their fam-
ily members and most were deemed totally non-
adherence or poorly adherence to medication (n = 57,
85 % in AT and n = 60, 90 % in TAU).
There were no significant differences on the baseline
mean values of the outcome measures (ITAQ, PANSS,
SLOF, ARS, ITAQ, and frequency and duration of re-
hospitalisations) and the DAI between two groups
[t(133) = 1.23–1.81, p > 0.12), and between two CPNS
[t(132) = 1.20–1.98, p > 0.10], indicating no-covariant ef-
fects. There were about 1.6 times (SD = 1.5) of psychi-
atric hospitalisations over the past 4 months in both AT
and TAU; from which, around 60 % were under ‘com-
pulsory’ admission (66 and 67 %, respectively). There
were no statistically significant differences in the amount
and types of atypical versus conventional anti-psychotics
(and other psychotropic drugs) between two groups at
T0-T3 (using ANOVA or Chi-square test, p > 0.20).
Treatment effects of adherence therapy
The results of the outcome measures at baseline and
three post-tests in both AT and TAU are summarised
in Table 3. As indicated in Table 3 (using a Bonferro-
ni’s adjusted alpha level of 0.01), there were statisti-
cally significant interaction (group x time) treatment
effects of AT, which included: improvements in both the
insight into illness/treatment [ITAQ score, F(1127) = 10.98,
p < 0.001, Wilks’ λ = 0.35, partial η2 = 0.40] and functioning
[SLOF score, F(1127) = 8.90, p < 0.005, Wilks’ λ = 0.30, par-
tial η2 = 0.29], and reductions in symptom severity [PANSS
score, F(1127) = 10.10, p < 0.003, Wilks’ λ = 0.33, par-
tial η2 = 0.32] and duration of re-hospitalisations
[F(1127) = 8.80, p < 0.005, Wilks’ λ = 0.29, partial η2 = 0.28],
when compared with TAU. In addition, the medication ad-
herence rate of the participants in AT significantly greater
improved over time [ARS score, F(1127) = 9.10, p < 0.005,
Wilks’ λ = 0.32, partial η2 = 0.30], when compared with
those in TAU. An examination of the adjusted mean scores
at T0-T3 (Fig. 2) indicated that the AT group reported
much very consistently positive improvements in ITAQ,
SLOF and PANSS scores and duration of re-
hospitalisations; whereas, the TAU group indicated progres-
sive mild to moderate negative changes of mean scores in
most of their outcome scores over the 18-month follow-up.
Although the average number of re-hospitalisations at T1 –
T3 did not indicate any significant difference between the
two study groups (H = 3.47, df = 3, p = 0.092), the total
numbers of participants in the AT group who had at least
one hospitalisation had greater and more consistent reduc-
tions from T1 to T3, when compared with the TAU group;
that is, 48 (74 %) and 48 (76 %) at T1, 34 (52 %) and 50
(79 %) at T2, and 31 (48 %) and 46 (73 %) at T3, accord-
ingly. At T0-T3 measurements, the participants’ number of
re-hospitalisations ranged 0–3 times for AT and 0–4 times
for TAU; whereas, its median values for AT reduced from 2
to 1 and for TAU, maintained at 2.
There were also significant statistical differences on
the mean scores of the two PANSS subscales between
the study groups at T1-T3 (see Fig. 3). Participants in
the AT reported significantly greater improvements in
both positive symptoms, F(2127) = 10.85, p < 0.001, and
negative symptoms, F(2125) = 9.14, p < 0.005, with effect
sizes (η2) of 0.38 and 0.30 (large effects) [26],
respectively.
Results of Helmert’s contrasts tests indicated that
when compared with TAU, AT participants had
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Table 2 Demographic and clinical characteristics of participants at baseline (N = 134)
Characteristics AT (n = 67) f (%) TAU (n = 67) f (%) χ 2, P
Gender Male 35 (52.24) 36 (53.73) 1.25, 0.25
Female 32 (47.76) 31 (46.27)
Age mean, s.d. 29.13, 9.87 28.23, 9.23
18–29 23 (34.33) 22 (32.84) 1.32, 0.23
30–39 31 (46.27) 32 (47.76)
40–49 10 (14.93) 9 (13.43)
50 or above 3 (4.48) 4 (5.97)
Diagnosis Schizophrenia 39 (58.21) 41 (61.19) 1.40, 0.21
Other psychotic disorders 28 (41.79) 26 (38.81)
Employment status Employed (Full-time) 28 (41.79) 24 (35.82) 1.52, 0.17
Employed (Part-time) 17 (25.37) 19 (28.36)
Unemployed 17 (25.37) 18 (26.87)
Others (e.g., intermittent job) 5 (7.46) 6 (8.96)
Education level Primary school 13 (19.40) 12 (17.91) 1.12, 0.28
Secondary school 44 (65.67) 42 (62.67)
University/College 10 (14.93) 13 (19.40)
Monthly household mean, s.d. 17,915, 6,594 16,880, 6,901 1.30, 0.22
income (HK$)a <10,000 9 (13.43) 8 (11.94)
10,001–20,000 31 (46.27) 30 (44.78)
20,001–30,000 21 (31.34) 21 (31.34)
>30,000 6 (8.96) 8 (11.94)
Duration of illness (months) mean, s.d., range 27.71, 10.10,3–36 months 28.12, 10.08,4–36 months
<6 18 (26.87) 20 (29.85) 1.19, 0.26
6–12 19 (28.35) 18 (26.87)
13–24 18 (26.87) 16 (23.88)
25–36 12 (17.91) 13 (19.40)
Treatment setting Outpatient department 66 (98.50) 67 (100.00) 1.87, 0.13
(other than CPNS) Day Hospital/Centre 10 (14.93) 11 (16.42)
Social welfare and finance 45 (67.17) 48 (71.64)
Individual/family counselling 14 (20.90) 12 (17.91)
Others (e.g., recreational and social
activities and crisis intervention)
12 (17.91) 14 (20.90)
Type of medication Conventional antipsychotics 22 (32.84) 20 (29.85) 1.13, 0.28
Atypical antipsychotics 30 (44.78) 32 (47.76)
Blended modec 15 (22.39) 15 (22.39)
Dosage of medicationb High 15 (22.39) 13 (19.40) 1.19, 0.27
Medium 42 (62.69) 43 (64.18)
Low 10 (14.92) 11 (16.42)
Accommodation Private household 22 (32.84) 24 (35.82) 1.83, 0.11
Public housing 31 (46.27) 30 (44.78)
Others (e.g., compassionate and
long-stay care)
14 (20.90) 13 (19.40)
AT Adherence Therapy, TAU Treatment as usual
aUS$1 = HK$7.8
bPatients were taking more than one type of psychotropic medication such as the use of either conventional and atypical antipsychotics, or atypical
antipsychotics and anti-depressants or anxiolytics
cDosage levels of anti-psychotic medications were compared with the average dosage of medication taken by schizophrenic patients in haloperidol-equivalent
mean values [19]
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significant greater changes (improvements) at the post-
tests on:
(a) Insight into illness/treatment (ITAQ score)
significantly increased at T1-T3 (Mean differences =
2.9, 3.3 and 9.8; SE = 0.9–3.2); whereas, the TAU
group indicated slight changes in their insight over
time;
(b)Symptom severity (PANSS score) significantly
reduced at T1-T3 (Mean differences = 12.1, 17.0 and
23.8; SE = 1.0–1.9) and for the TAU, it slightly in-
creased at T1 and T2;
Table 3 Outcome measure scores at T0-T3 and results of repeated-measures ANOVA and Kruskal-Wallis tests for two study groups
AT (n = 65) TAU (n = 63) F(1,127) P Effect size (Partial η2)
Study Outcome Mean s.d. Mean s.d.
ITAQ (0 – 33) a
T0 13.3 3.5 14.3 5.0 10.98 0.001 0.40
T1 17.5 5.7 14.6 4.9
T2 20.9 6.1 14.2 7.5
T3 24.8 5.3 15.0 8.8
SLOF (43–215)
T0 139.8 14.1 139.8 15.1 8.90 0.005 0.29
T1 158.0 20.8 140.8 22.0
T2 177.2 22.0 130.1 24.3
T3 183.2 20.1 129.1 28.8
PANSS (30–210)
T0 80.6 7.5 81.6 6.9 10.10 0.003 0.32
T1 74.8 7.0 86.9 8.8
T2 68.1 8.9 85.0 9.9
T3 59.0 10.1 82.8 11.6
ARS (1 – 5)
T0 1.3 1.1 1.3 1.1 9.10 0.005 0.30
T1 1.7 1.0 1.3 1.1
T2 1.9 1.1 1.4 1.2
T3 2.5 1.3 1.5 1.1
Re-hospitalisation
Frequency b
T0 2 c (0–3) c 2 c (0–3) c 3.47 d 0.092
T1 2 (0–3) 2 (0–4)
T2 1 (0–2) 2 (0–3)
T3 1 (0–2) 2 (0–3)
Duration e
T0 9.9 5.3 9.2 6.1 8.80 0.005 0.28
T1 8.7 5.1 9.8 6.8
T2 8.0 6.6 14.2 8.2
T3 7.0 6.0 15.0 9.9
AT Adherence Therapy, TAU Treatment as Usual or Psychiatric Outpatient Care
T0 baseline measurement at the start of intervention, T1 2 weeks after intervention, T2 6 months after intervention, T3 18 months after intervention
ARS Adherence Rating Scale, ITAQ Insight and Treatment Attitude Questionnaire, PANSS Positive and Negative Syndrome Scale SLOF Specific Level of
Functioning scale
a Possible range of scores of each scale indicated in parenthesis
b Average number of re-admissions to a psychiatric inpatient unit in the previous 4 months at T0-T3
c Median and range of the frequency of re-hospitalisations
d H value of Kruskal-Wallis test (df = 3)
e Duration or length of readmissions to a psychiatric inpatient unit in terms of average number of days of hospital-stay over the previous 4 months at four time points
The test (Chi-square or t) and p values are in bold if the subject characteristics are significantly different between groups
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(c)Level of functioning (SLOF score) significantly
increased at T2 and T3 (Mean differences = 47.1
and 54.1; SE = 2.4 and 8.7, respectively);
(d)Medication adherence rate (ARS score)
significantly increased at T2 and T3 (Mean
differences = 0.5 and 1.0; SE = 0.1 and 0.2,
respectively); and
(e)Duration (days) of re-hospitalisations significantly re-
duced at T2 and T3 (Mean differences = 6.2 and 8.0;
SE = 2.4 and 3.8, respectively); whereas for the TAU, it
was consistently increased (from 9.2 at T0 to 15.0 at T3).
There were no significant differences in the types and
doses of anti-psychotic medication and nature of
Fig. 2 Five figures show the mean scores of each of the five study outcomes, including symptom severity (PANSS score), level of functioning
(SLOF score), insight into illness/treatment (ITAQ score), duration of re-hospitalisations, for two study groups at baseline (T0) and 2 weeks,
6 months and 18 months follow-ups (T1-T3). These five study outcomes were found significantly greater improvements among the participants
in adherence therapy, when compared to those in treatment as usual
Fig. 3 Two figures shows the mean scores of the positive and negative symptoms in PANSS for two study groups at baseline (T0) and 2 weeks,
6 months and 18 months follow-ups (T1-T3). The mean scores of these two subscales of the PANSS were found significantly greater improvements among
the participants in adherence therapy, when compared to those in treatment as usual
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admission (voluntary/compulsory), as well as the types
and amount of participation in other psychosocial inter-
ventions, between the two groups across four times of
measurements (using repeated-measures ANOVA test or
Kruskal Wallis test, p > 0.15). During the study period,
the AT and TAU groups received other community men-
tal health services, mainly including social skills and em-
ployment training (n = 23 and 25), family support group
(n = 14 and 12), individual or family counselling service
(n = 10 and 15), and day hospital and social and recre-
ational centre services (n = 11 and 15).
There were also no significant differences on the study
outcomes between the two study groups or between the
participants within the AT group in terms of the six nurse
therapists (CPNs), where F values of the repeated-measures
ANOVA tests ranged from 1.31 to 2.89, p = 0.11–0.30).
Intra-class correlations of outcome measures between
CPNs in each of the two study settings were similar and
very small, ranging 0.001 to 0.0005, which indicated very
minimal nested design effects (i.e., between the six nurse
therapists) on the outcomes [27].
Discussion
Effects of motivational interviewing-based adherence
therapy
The findings of this controlled trial provide evidence on
the significant positive effects of this 6-session adherence
therapy (AT) for people with schizophrenia spectrum
disorders in community mental health care. The results
supported the study hypotheses that when compared
with those in usual psychiatric outpatient care, the par-
ticipants in AT indicated much better patient outcomes
(i.e., psychotic symptoms, medication adherence, insight
into illness/treatment, functioning, and length of psychi-
atric re-hospitalisations) with large effect sizes (partial
η2 = 0.28–0.40) [26] over 18-month follow up. These
findings also suggest that adherence therapy originated
from Western culture [7, 25] can be effective not only in
people with addictive and behavioural problems [6, 28],
but also in patients with schizophrenia and other psych-
otic disorders.
The AT used in this study based on motivational inter-
viewing technique is one of few interventions attempted
globally to enhance patients’ insight into their medica-
tion and/or other treatments and motivation to self-
manage their medication and illness-related behaviours
in people with schizophrenia spectrum disorders. This
AT has demonstrated promising patient outcomes over
a long-term (18 months) follow-up. Whilst recent litera-
ture on adherence therapy in Thailand and European
countries can only show positive effects on psychotic pa-
tients’ medication adherence and relapse rate over
<12 months follow-up [8–10], the findings in this study
provide strong evidence on this promising approach to
AT to significantly enhance these patients’ insight into
their illness and motivation to change positively in their
adherence behaviours. Therefore, it demonstrates sub-
stantive improvements in a wide variety of patient out-
comes, including psychotic symptoms, duration of
hospitalisations and psychosocial functioning.
Although the patients’ hospitalisation rate in terms of
frequency of re-admissions in psychiatric hospital/unit at
T1 – T3 did not differ between groups, the duration of
re-hospitalisations of the TAU group were consistently
and significantly worsened, and their symptom severity
(PANSS score) and functioning (SLOF score) were grad-
ually deteriorated, over the 18-month follow-up. High
percentages of the participants in the TAU had at least
one hospitalisation over the follow-up (T1-T3: 76, 79
and 73 %, accordingly), whereas, the AT group reduced
from 74 % at T1 to 48 % at T3. The results in the TAU
group showing gradual mild deterioration in mental
state and functioning over the 18-month follow-up
might reflect the cumulative effects of non-adherence to
medication to these patients over time. As all the pa-
tients were within 3 years and/or first-episode of illness
at recruitment and low to medium dosages of anti-
psychotic medications, it needs time for them to show
progressive deterioration in psychotic symptoms and
other clinical outcomes across time as the result of poor
medication and treatment adherence. These results
would support the recommendation of recent practice
guidelines for the importance of ensuring accessibility
and adherence to treatment in the first 3 years of psych-
osis [1–3].
However, it remains unanswered whether the signifi-
cant improvements in patient outcomes are solely the ef-
fect of AT or a combined effect of this therapy and
other psychosocial and family interventions and/or psy-
chiatric treatments that are considered potentially thera-
peutic but had not yet been included in the data
analysis. Further research with structured, integrated re-
habilitation programme to explore the therapeutic ef-
fects of its individual components, and/or compare the
effects between the components, is recommended; and
one of which will be the AT used in this study.
Fidelity of adherence therapy
The AT was conducted by six trained community psy-
chiatric nurses (three from each of the two CPNS under
study) who received two full-day training, together with
supervised practices on four patients, according to the
AT instructor programme. However, it was guided by a
validated manual and delivered by these six nurse thera-
pists with a high level of treatment fidelity (i.e., rated
‘competent’ in >92 % of the items in the AT manual). In
contrast to recent studies of AT, there were very high
completion rate (95 % versus 50–70 % in other studies)
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[7–10] of the intervention and on other hand, low at-
trition rate (4 % versus 15–30 %) [7–9], over an 1-year
follow-up. This AT showed much clear benefits in
terms of psychopathology and treatment insight and
adherence for people with acute to approaching
chronic schizophrenia (3–36 months of illness), indi-
cating poor medication adherence and moderate levels
of psychotic symptoms and functioning. The sample
recruited (>70 % poorly adhered to medication at
baseline) was comparable and thus representative to
the largest proportion of psychotic patients found dur-
ing the first few years of illness [20, 29]; this has also
responded to the limitation of recent AT studies in
which most participants reported mildly/moderately
impaired in medication adherence [5, 9, 10].
Strengths of adherence therapy
This is one of very few clinical trials of effective adher-
ence therapy currently available for improving patients’
insights into and adherence to anti-psychotic medication
in schizophrenia and showing benefits in a variety of
patient outcomes such as psychotic symptoms, re-
hospitalisation rates and psychosocial functioning. This
effective intervention is particularly important to these
patients who would have a high relapse or recurrence
rate (70–90 %) over the first few years after discharge
from hospital or acute stage of illness [23, 30]. It is also
worthwhile to note that this AT can improve not only
these patients’ positive symptoms (e.g., hallucination and
delusion) [7, 8, 10] but also treatment-resisted negative
symptoms (e.g., amotivation, anhedonia and socially
withdrawn). This result could be due to the effect of mo-
tivational interviewing technique in which the partici-
pants were facilitated non-judgementally to explore and
resolve ambivalences on management of their illness,
treatment and life problems and engaged with their in-
trinsic motivation to change treatment/illness-related
behaviours such as medication adherence and self-care
[28]. Genuine empathy, acceptance and envisioning for a
better future in motivational interviewing can be helpful
to access motivation and foster therapeutic growth and
change specific behaviours regarding those negative
symptoms [10, 28].
Several studies reported an oversight of the impact of
clinicians’ characteristics in treatment effectiveness,
recommending that further studies utilise patient-
centred working staff who were already part of the pa-
tient’s clinical team [2, 16, 31]. The AT in this study was
administered by the community psychiatric nurses of
the randomly selected participants after baseline mea-
surements had been taken. This AT were also modified
to more focus on participant involvement during its sec-
ond half or third phase (3 sessions), echoing the import-
ance of enhancing a sense of self-control for the success
in treatment, as suggested in studies of psychosocial in-
terventions [2, 23, 28].
Recent reviews on AT noticed that effects of AT
decay over time, or find that therapy over a course of
5–6 sessions was insufficient to be effective [7, 16, 31].
Importantly, our results can conclude a sustained ef-
fect across most outcome measures, with the observa-
tion of significantly reduced re-hospitalisations at the
18-month follow-up. Previous findings suggested that
the effects of adherence therapy targeting at patients’
beliefs and insights into their illness/treatments
seemed to be inconclusive [6, 9, 25]; whereas, this
study confirms that such approach can be effective to
outpatients with moderate psychotic symptoms in the
early stage of schizophrenia spectrum disorders. The
findings also echo the recommendations by Gray et al.
[31] that adherence modifying factors essentially
centred on improved self-determination, patient
choice, and shared decision making. Further, AT is
able to embody the advantages of continuous boosting
up patient’s motivation to manage barriers to medica-
tion/treatment on top of essential psychosocial sup-
port and psychopharmacological education. This
therapy can also acknowledge the utmost importance
of patient involvement in treatment decisions, under-
standing about their treatments/medications used, and
possible consequences of adherence or non-adherence
to medication such as risk of relapse [2, 32], thus
allowing patients to decide with fully informed, volun-
tary choices in taking their medication.
An investigation of not only individual patients’ per-
ceptions of and satisfaction with the AT but also the
therapeutic process, in terms of motivators and chal-
lenges and degrees of engagement and involvement [23],
are essential to better understand the active ingredients
of a motivation-enhancing behavioural intervention. Fur-
ther investigation of the relationships between the
perceived benefits/strengths of AT and its major compo-
nents and therapeutic mechanisms can be performed
using individual/group interviews and/or structured ob-
servations [9, 16]. Finally, with a longer-term follow-up
(e.g., 24 months), other sustained benefits or outcomes
used in psychosocial intervention studies such as im-
provement in global functioning, satisfaction with men-
tal health services and quality of life, as well as its cost-
effectiveness, can be investigated.
Limitations of the study
A few limitations are noted in this study. First, over
60 % of the patients in the two CPNS were found not
eligible to or excluded from the study, although the re-
fusal rate was very low (4.5 %) when approached 650 pa-
tients for study participation. These non-participants
might not be similar to the participants and their
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responses to the AT in this study, thus reducing the gen-
eralisability of the findings. In addition, the patients who
were volunteered to participate were mainly those with
full- or part-time employment (64–67 %), relatively
shorter duration of illness (>55 % having less than 1 year
of illness) and satisfactory accommodation and family
support, and hence might be highly motivated to attend
the six AT sessions (mean = 4.6 sessions, SD = 1.1). The
patterns of socio-demographic and illness characteristics
and levels of medication adherence or motivation to
change might also not be representative to other Chin-
ese populations with psychotic disorders. Therefore, this
selective sampling should be cautioned when compari-
sons are made between this and other studies of medica-
tion management programmes.
Second, all of the outcome measures were reported by
the participants, except the level of adherence rated by
the research assistant and community psychiatric nurse.
There were no biological assays such as hair, urine or
blood specimens, which are considered more objective
and reliable measurements [8, 10, 31], to validate or con-
firm with the non-invasive ones in this study. Third,
multi-level modelling of data should have been per-
formed for repeated-measures outcome analysis in this
study to reduce the errors or problems with ANOVA
test on sphericity assumption (constant variances of dif-
ference scores), nested design effect (sampling hierarchy
in relation to more than one nurse therapists and set-
tings used), and requirements for complete designs and
data sets (or very few missing data) [33]. Last, the partic-
ipants and nurse therapists were not blind to the inter-
vention taken and Hawthorne effect (e.g., preconceived
benefits of AT) among them could not be excluded.
Conclusions
AT can be a systematic, multifaceted and client-centred
therapy model with evidenced benefits and applicability
to outpatients with schizophrenia spectrum disorders in
a Chinese population. This therapy can also be provided
by other mental health professionals if appropriately
trained and become an integral part of the community-
based rehabilitation programme provided by outpatient
care service, together with pharmacological and other
psychiatric treatments. In view of this motivational
interviewing-based AT being shown effective in Chinese
patients with schizophrenia, it deserves further research
in the suitability for more representative samples and
wider and more systematic implementation in commu-
nity mental health care for patients with diverse charac-
teristics, levels of medication adherence and illness
groups.
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